https://www.prnewswire.com/news-releases/gentibio-announces-first-participant-dosed-in-polaris-phase-1-clinical-trial-of-gnti-122-in-recently-diagnosed-type-1-diabetes-302716586.html
GentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in...
/PRNewswire/ -- GentiBio, Inc., a clinical-stage biotechnology company pioneering engineered, antigen-specific regulatory T cell (EngTreg) therapies, today...